Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 18th.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) last issued its quarterly earnings data on Monday, May 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter. On average, analysts expect Quoin Pharmaceuticals to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Get
Quoin Pharmaceuticals alerts:
Quoin Pharmaceuticals Stock Down 1.3 %
Shares of QNRX stock opened at $4.72 on Tuesday. Quoin Pharmaceuticals has a 52-week low of $3.58 and a 52-week high of $444.00. The company has a 50-day simple moving average of $5.87 and a two-hundred day simple moving average of $11.07.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned approximately 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 21.72% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on QNRX shares. LADENBURG THALM/SH SH started coverage on shares of Quoin Pharmaceuticals in a research report on Friday, May 6th. They issued a "buy" rating and a $25.00 price objective for the company. Maxim Group reduced their target price on shares of Quoin Pharmaceuticals to $25.00 in a research report on Thursday, May 26th.
About Quoin Pharmaceuticals
(Get Rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
See Also
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- Is Uber Bait and Switching Its Way to Profitability?
- Is Ford About To Crush Workhorse Group?
- Is it Time to Throw in the Towel On Coinbase Stock?
- The Five Hottest Calls From The Q2 Earnings Season
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 18th.
納斯達克(股票代碼：QNRX-GET Rating)定於8月18日(星期四)開市前公佈季度收益報告。
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) last issued its quarterly earnings data on Monday, May 23rd. The company reported ($2.50) earnings per share (EPS) for the quarter. On average, analysts expect Quoin Pharmaceuticals to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
納斯達克(QNRX-GET Rating)上一次發佈季度收益數據是在5月23日(星期一)。該公司公佈了該季度每股收益(EPS)(2.50美元)。分析師平均預計Quoin製藥公司本財年每股收益為-7美元，下一財年為-5美元。
Get
Quoin Pharmaceuticals
alerts:
Quoin Pharmaceuticals Stock Down 1.3 %
Shares of QNRX stock opened at $4.72 on Tuesday. Quoin Pharmaceuticals has a 52-week low of $3.58 and a 52-week high of $444.00. The company has a 50-day simple moving average of $5.87 and a two-hundred day simple moving average of $11.07.
週二，QNRX股票開盤報4.72美元。Quoin PharmPharmticals的52周低點為3.58美元，52周高位為444.00美元。該公司的50日簡單移動均線切入位在5.87美元，200日簡單移動均線切入位在11.07美元。
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned approximately 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 21.72% of the company's stock.
一家對衝基金最近購買了Quoin PharmPharmticals股票的新股份。根據Virtu Financial LLC最近提交給美國證券交易委員會的文件，該公司在第一季度購買了Quoin PharmPharmticals，Ltd.(美國證券交易委員會代碼：QNRX-GET Rating)的新頭寸。該機構投資者購買了42,665股該公司股票，價值約57,000美元。在最近一個報告期結束時，Virtu Financial LLC擁有Quoin製藥公司約0.51%的股份。機構投資者和對衝基金持有該公司21.72%的股票。
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on QNRX shares. LADENBURG THALM/SH SH started coverage on shares of Quoin Pharmaceuticals in a research report on Friday, May 6th. They issued a "buy" rating and a $25.00 price objective for the company. Maxim Group reduced their target price on shares of Quoin Pharmaceuticals to $25.00 in a research report on Thursday, May 26th.
許多股票研究分析師發佈了關於QNRX股票的報告。拉登堡THALM/SH在5月6日星期五的一份研究報告中開始對Quoin製藥公司的股票進行報道。他們對該公司的評級為“買入”，目標價為25美元。Maxim Group在5月26日週四的一份研究報告中將Quoin PharmPharmticals的股票目標價下調至25.00美元。
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Quoin PharmPharmticals，Ltd.是一家專業製藥公司，專注於開發治療罕見和孤兒疾病的產品。該公司的主導產品是QRX003，一種治療Netherton綜合徵的外用洗劑。它還開發了用於治療營養不良性大皰性表皮鬆解症的QRX004；以及治療罕見皮膚病的QRX006。
See Also
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- MarketBeat Podcast: ESG – Profitably Invest Your Values
- Is Uber Bait and Switching Its Way to Profitability?
- Is Ford About To Crush Workhorse Group?
- Is it Time to Throw in the Towel On Coinbase Stock?
- The Five Hottest Calls From The Q2 Earnings Season
- 免費獲取StockNews.com關於Quoin PharmPharmticals的研究報告(QNRX)
- MarketBeat播客：ESG--有利可圖地投資你的價值
- 優步是否正在成為誘餌，並轉向盈利？
- 福特即將摧毀主力集團嗎？
- 是時候對Coinbase Stock認輸了嗎？
- 第二季度財報季最熱門的五個電話
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Quoin PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Quoin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
